ADVANCE infectious diseases pharmacy through collaboration, research and education and LEAD antimicrobial stewardship to OPTIMIZE the care of patients with infections in every practice setting

  • Home
  • Live CE Webinar: Combining Forces: Maximizing Efficacy with Daptomycin and Beta-Lactam Dual Therapy for Gram-Positive Infections

Live CE Webinar: Combining Forces: Maximizing Efficacy with Daptomycin and Beta-Lactam Dual Therapy for Gram-Positive Infections

  • 14 Nov 2024
  • 1:00 PM - 2:00 PM

Thursday, November 14, 2024
12:00 pm – 1:00 pm CT / 1:00 pm – 2:00 pm ET

Register 

Despite historical precedence and the utilization of varied mechanisms of action and toxicity profiles, the amalgamation of antimicrobials demands careful consideration. Recognizing the pivotal role of dual therapy in clinical practice, ongoing education on this subject is indispensable to improve patient outcomes and prevent unnecessary toxicity from specific combinations. This webinar not only imparts pharmacists with essential insights into the relevant mechanisms of resistance of Staphylococcus aureus and Enterococcus spp but also provides pharmacological strategies to overcome these challenges. Additionally, it will compare the combination of daptomycin and ceftaroline with other beta-lactam antibiotics. Through patient case scenarios and discussions, this program will illustrate clinical considerations for optimizing dual therapy in treating MRSA and VRE infections, thereby empowering pharmacists and healthcare professionals with the critical knowledge and skills needed to enhance patient care in the context of evolving bacterial resistance. Attendees will have an opportunity for Q&A at the end of the presentation.

Target Audience:

This activity was planned to meet the educational needs of infectious diseases pharmacists. The educational content is also relevant for other healthcare practitioners working in infectious diseases patient-care settings who are directly involved in treatment decisions.

Learning Objectives:

  • Review antimicrobial resistance mechanisms found in Staphylococcus aureus and Enterococci and pharmacological strategies to overcome resistance based on proposed mechanisms of synergy and supporting literature.
  • Compare evidence for daptomycin in combination with ceftaroline versus other beta-lactam antibiotics as synergistic regimens against Staphylococcus aureus and Enterococci.
  • Evaluate clinical considerations essential for optimizing dual antimicrobial therapies.

Faculty:

Lynn Wardlow, PharmD, MBA, MS, BCIDP
Specialty Practice Pharmacist, Infectious Diseases; PGY2 Infectious Diseases Residency Program Director
The Ohio State University Wexner Medical Center
Columbus, Ohio

Accreditation:

Pharmacist

The Society of Infectious Diseases Pharmacists (SIDP) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

UAN: 0672-0000-24-025-L01-P
CPE credit: 1.0 contact hour (0.1 CEU)
Type of activity: Application
Activity Fee: SIDP Member: Free / Non-Member: $10

To receive CE credit, participants must view the CE content, complete a post-test, and complete an activity evaluation. Proof of completion will be submitted to NABP CPE Monitor.

Per ACPE requirements, CPE credit must be claimed within 60 days of being earned. Participants are responsible for verifying credits were transferred successfully to your NABP eProfile account before the ACPE 60-day deadline. After the 60 day deadline, SIDP will no longer be able to report your credit(s) for this activity.

Funding:

This activity is provided by SIDP. No external funding was received for this activity.

Disclosures:

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, SIDP asks all individuals involved in the development and presentation of CE activities to disclose all financial relationships with ineligible companies. All relevant financial relationships have been mitigated prior to the CE activity. The following financial relationships have been disclosed:

  • Dr. Wardlow’s disclosures will be announced prior to the start of the activity.
  • SIDP planners, staff and other individuals who are in a position to control the content of this CE activity have no relevant financial relationships with an ineligible company to disclose.

Disclaimer:

Faculty members are asked to disclose when any unlabeled/investigational use of pharmaceuticals and devices is being discussed. This activity is intended for educational purposes and should not be used as a substitute for care or advice from a professional. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of SIDP.

The planners and faculty of this continuing education activity have made all reasonable efforts to ensure the accuracy of the information presented in accordance with the latest available scientific knowledge at the time of publication. Healthcare professionals should verify all information and data with recommendations of other authorities before treating patients or employing any therapies described in this continuing education activity.


Register 


Society of Infectious Diseases Pharmacists •  PO Box 1488, Warrenville, IL 60555
(331) 248-7888sidp@affinity-strategies.com
Proudly Managed by Affinity Strategies

Powered by Wild Apricot Membership Software